Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension…

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock (NASDAQ:AKRO)

This article was written by Follow Avisol Capital Partners is made up of a team of…

Akero: Reversal Of Cirrhosis With EFX Is A “First” In F4 MASH Patients (NASDAQ:AKRO)

This article was written by Follow Terry Chrisomalis is a private investor in the Biotech sector…